MERS coronavirus
Generated by GPT-5-miniExpansion Funnel Raw 76 → Dedup 16 → NER 13 → Enqueued 9
| MERS coronavirus | |
|---|---|
| Name | MERS coronavirus |
| Virus group | Group IV (positive-sense single-stranded RNA viruses) |
| Family | Coronaviridae |
| Genus | Betacoronavirus |
| Species | Middle East respiratory syndrome-related coronavirus |
| Hosts | Humans, dromedary camels |
| Discovered | 2012 |
| Location | Saudi Arabia |
MERS coronavirus is a zoonotic betacoronavirus first identified in 2012 in Jeddah and Riyadh, Saudi Arabia, after severe respiratory infections were reported at King Saud University-affiliated hospitals and national public health agencies. The virus caused sporadic outbreaks with high case-fatality ratios that prompted response from the World Health Organization, the Centers for Disease Control and Prevention, and regional ministries of health, while stimulating research at institutions such as University of Hong Kong, Imperial College London, and the National Institute of Allergy and Infectious Diseases. Initial investigation linked the agent to dromedary camels and to human clusters associated with healthcare settings like King Fahd Medical City and Al-Madinah hospitals.
Virology and Genome
MERS coronavirus is an enveloped, positive-sense single-stranded RNA virus within the Betacoronavirus genus, related to viruses studied at The Pirbright Institute and characterized using sequencing platforms deployed by Sanger Institute and Wellcome Trust. Its approximately 30 kilobase genome encodes structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N), which were mapped during collaborative projects involving Johns Hopkins University and Pasteur Institute. The viral spike glycoprotein engages the cellular dipeptidyl peptidase 4 receptor, a mechanism clarified in structural studies at Max Planck Institute and Harvard University, informing antiviral development by industry partners such as Moderna and Regeneron. Comparative genomics with strains from United Arab Emirates and Qatar revealed lineage diversity and recombination events analogous to earlier coronavirus research at University of Wuhan and Yale University.
Epidemiology and Transmission
Epidemiologic investigation implicated zoonotic spillover from dromedary camels in regions including Saudi Arabia, Jordan, Oman, and United Arab Emirates, supported by serosurveys conducted by teams from King Abdullah University Hospital and WHO Eastern Mediterranean Regional Office. Human-to-human transmission has occurred primarily in household clusters and nosocomial outbreaks at facilities such as Al-Hasa Hospital, with amplification described during events investigated by European Centre for Disease Prevention and Control and the Korean Centers for Disease Control and Prevention following the 2015 South Korea MERS outbreak. Travel-associated cases were reported through ports of entry linked to Dubai International Airport and Heathrow Airport, prompting screening measures by agencies including International Air Transport Association and United States Customs and Border Protection. Surveillance data compiled by Global Outbreak Alert and Response Network and academic groups at London School of Hygiene & Tropical Medicine informed risk assessments used by the United Nations.
Clinical Presentation and Pathogenesis
Clinical presentations range from asymptomatic infection to severe acute respiratory illness with pneumonia and acute respiratory distress syndrome, documented in cohorts treated at King Abdulaziz Medical City and Seoul National University Hospital. Severe disease disproportionately affected older adults and persons with comorbidities such as diabetes, chronic renal disease, and immunosuppression, aligning with comorbidity studies from Mayo Clinic and Cleveland Clinic. Pathogenesis involves viral replication in respiratory epithelium, immune dysregulation, and inflammatory lung injury described in experimental models at Rockefeller University and Ragon Institute, paralleling insights from studies of SARS coronavirus and informing organ-specific complications reported by Mount Sinai Hospital clinicians.
Diagnosis and Laboratory Testing
Diagnostic algorithms rely on nucleic acid amplification tests targeting upE and ORF1a regions, as validated by reference laboratories at CDC Atlanta and Public Health England, and deployed on platforms developed by Roche and Cepheid. Serologic assays using recombinant spike protein were standardized in collaborations among WHO Collaborating Centres and university laboratories at University of Pennsylvania to detect prior exposure in serosurveys. Viral culture requires biosafety level 3 containment as practiced at CDC Atlanta and National Microbiology Laboratory, Canada, while genomic sequencing for surveillance has been performed by consortia including GISAID members and the European Nucleotide Archive.
Treatment, Management, and Vaccines
No antiviral has been universally approved specifically for the virus; management emphasized supportive care in intensive care units at Cleveland Clinic and Charité – Universitätsmedizin Berlin. Investigational therapeutics included repurposed agents evaluated in trials coordinated by WHO and academic centers such as University of Oxford and NIH Clinical Center, while monoclonal antibodies and vaccine candidates advanced through preclinical studies at Vaccine Research Center and biotechnology firms like Inovio Pharmaceuticals. Vaccine platforms leveraging viral vectors, mRNA, and protein subunits were explored with involvement from National Institutes of Health and private partnerships, drawing on prior vaccine development efforts against Ebola virus and SARS-CoV-1.
Prevention, Public Health Response, and Control Measures
Prevention strategies combined camel herd management policies advised by Food and Agriculture Organization and World Organisation for Animal Health with infection prevention protocols in healthcare settings promoted by WHO and Centers for Disease Control and Prevention. Outbreak control relied on case identification, contact tracing by public health authorities such as Ministry of Health (Saudi Arabia) and Korean Ministry of Health and Welfare, and travel advisories coordinated with International Civil Aviation Organization. Preparedness initiatives integrated lessons from responses to SARS epidemic and H1N1 pandemic and emphasized One Health collaboration among veterinary services, public health institutes, and research centers including Rockefeller Foundation-funded programs.